Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.

about

Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.

Item

http://www.wikidata.org/entity/Q45861270

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Further evidence of the limita ...... in Time to monitor Argatroban.

@en

Further evidence of the limita ...... in Time to monitor Argatroban.

@nl

type

Item

label

Further evidence of the limita ...... in Time to monitor Argatroban.

@en

Further evidence of the limita ...... in Time to monitor Argatroban.

@nl

prefLabel

Further evidence of the limita ...... in Time to monitor Argatroban.

@en

Further evidence of the limita ...... in Time to monitor Argatroban.

@nl

P1476

Further evidence of the limita ...... in Time to monitor Argatroban.

@en

P2093

Joost J Van Veen

http://www.w3.org/2001/XMLSchema#string

Steve Kitchen

http://www.w3.org/2001/XMLSchema#string

Susan Guy

http://www.w3.org/2001/XMLSchema#string

P2860

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.

Venous limb gangrene and fatal hemorrhage: adverse consequences of HIT "overdiagnosis" in a patient with antiphospholipid syndrome.

Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia.

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.

Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients.

P31

scholarly article

P356

10.1111/BJH.14397

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2016-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27785784

http://www.w3.org/2001/XMLSchema#string